Immunogenicity and protective efficacy of affinity-purified Plasmodium falciparum exoantigens in Aotus nancymai monkeys.
Soluble Plasmodium falciparum polypeptides, affinity-purified from culture supernatant fluids using sequential immunoadsorptions employing both monoclonal and polyclonal antibodies, induced protective immunity against experimental falciparum malaria in Peruvian Aotus nancymai monkeys. Susceptible monkeys were vaccinated with polypeptides affinity-purified from supernatant fluids of P. falciparum Indochina I/CDC cultures. Eighteen animals (6 immunized with purified antigens plus adjuvants, 6 injected with only the adjuvant preparation, and 6 untreated) were challenged with whole blood containing monkey-adapted virulent organisms of the Indochina I/CDC strain. Selected hematologic, serologic and parasitologic profiles served as potential indicators of protection. This immunogen, when fortified with an aluminum hydroxide/Quil-A saponin adjuvant combination, elicited good antibody responses to major P. falciparum antigens. Protection in vaccinated animals was evidenced by a significantly limited reduction in hematocrit and hemoglobin levels and a relatively moderate course of infection after homologous needle-challenge with Aotus monkey-adapted P. falciparum parasites.
James
M A
MA
Department of Veterinary Pathobiology, University of Illinois, Urbana 61801.
Fajfar-Whetstone
C J
CJ
Kakoma
I
I
Buese
M M
MM
Clabaugh
G W
GW
Hansen
R
R
Ristic
M
M
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000737:chemistry / Q000276:immunology* / Q000302:isolation & purification; D001029:Aotus trivirgatus; D015153:Blotting, Western; D002846:Chromatography, Affinity; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D008288:Malaria / Q000517:prevention & control*; D008297:Male; D008970:Molecular Weight; D010963:Plasmodium falciparum / Q000276:immunology*; D016052:Protozoan Vaccines; D014611:Vaccination / Q000009:adverse effects
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D006454:Hemoglobins; D016052:Protozoan Vaccines